Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using
chemo-and radio-therapy modestly increases the overall survival of patients; however …

Tumor metabolism is emerging as a potential target for cancer therapies. This new approach
holds particular promise for the treatment of glioblastoma, a highly lethal brain tumor that is …

Glioblastoma (GBM) is a highly aggressive and lethal brain tumor with limited treatment
options, such as the chemotherapeutic agent, temozolomide (TMZ). However, many GBM …

Glioblastoma multiforme (GBM), a grade IV (WHO classification) malignant brain tumor,
poses significant challenges in treatment. The current standard treatment involves surgical …

Glioblastoma WHO IV (GBM), the most common primary brain tumor in adults, is a
heterogenous malignancy that displays a reprogrammed metabolism with various fuel …

Glioblastoma (GBM) is one of the most aggressive tumors of the central nervous system,
characterized by a wide range of inter-and intratumor heterogeneity. Accumulation of fatty …

Cancer drug resistance is one of the main barriers to overcome to ensure durable treatment
responses. While many pivotal advances have been made in first combination therapies …

The intricate cross-talks between tumor cells and their microenvironment play a key role in
cancer progression and resistance to treatment. In recent years, targeting pro-tumorigenic …

Temozolomide (TMZ) is currently the first-line chemotherapeutic agent for the treatment of
glioblastoma multiforme (GBM). However, the inherent heterogeneity of GBM often results in …

Glioblastoma multiforme (GBM) is one of the most aggressive forms of brain tumor,
characterized by a daunting prognosis with a life expectancy hovering around 12–16 …